Testing effectiveness (Phase 2)UnknownNCT03091933
What this trial is testing
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
Who this might be right for
Hematologic CancerRelapse LeukemiaRelapsed Adult ALL+6 more
Ciusss de L'Est de l'Île de Montréal 20